Department of Pharmacy, National Hospital Organization Sendai Medical Center, Sendai, Japan.
Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan.
Cancer Rep (Hoboken). 2020 Oct;3(5):e1258. doi: 10.1002/cnr2.1258. Epub 2020 Jun 17.
Eribulin therapy has recently attracted attention from various viewpoints, including quality of life, and is considered a standard therapy for inoperable or recurrent breast cancer. Although a reduction in renal function reportedly decreases total eribulin clearance, its association with dose-limiting toxicity and the reduction of neutrophils remain unclear.
This study was aimed at analyzing the association between decreased renal function prior to eribulin administration and the occurrence of neutrophil reduction and time to treatment failure in patients with breast cancer.
We retrospectively assessed patients with breast cancer, who underwent eribulin therapy between July 2011 and March 2018. Multivariate analysis revealed creatinine clearance <70 mL/min and serum albumin levels <3.9 mg/dL as predictive factors for neutrophil reduction. Even on increasing the relative dose intensity by these factors, no difference in time to treatment failure was observed, suggesting that treatment efficacy is potentially unaffected.
For continuous eribulin therapy, eribulin may need to be administered to individual patients in accordance with renal function and albumin levels before treatment initiation.
艾立布林治疗最近受到了多方面的关注，包括生活质量，被认为是不可切除或复发性乳腺癌的标准治疗方法。虽然据报道肾功能下降会降低总艾立布林清除率，但它与剂量限制毒性和中性粒细胞减少的关系仍不清楚。
本研究旨在分析乳腺癌患者艾立布林治疗前肾功能下降与中性粒细胞减少的发生以及治疗失败时间之间的关系。
我们回顾性评估了 2011 年 7 月至 2018 年 3 月期间接受艾立布林治疗的乳腺癌患者。多变量分析显示，肌酐清除率<70 mL/min 和血清白蛋白水平<3.9 mg/dL 是中性粒细胞减少的预测因素。即使通过这些因素增加相对剂量强度，治疗失败时间也没有差异，表明治疗效果可能不受影响。
对于连续的艾立布林治疗，在治疗开始前，可能需要根据肾功能和白蛋白水平，为每个患者制定个体化的艾立布林治疗方案。
